Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Asset Writedowns and Impairment: 2009-2021

Historic Asset Writedowns and Impairment for Cytokinetics (CYTK) over the last 3 years, with Dec 2021 value amounting to $2.8 million.

  • Cytokinetics' Asset Writedowns and Impairment changed negligibly% to $103,000 in Q3 2013 from the same period last year, while for Sep 2013 it was $412,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.8 million for FY2021, which is N/A change from last year.
  • Cytokinetics' Asset Writedowns and Impairment amounted to $2.8 million in FY2021, which was up 1,785,720.63% from $159.25 recorded in FY2010.
  • Cytokinetics' 5-year Asset Writedowns and Impairment high stood at $2.8 million for FY2021, and its period low was $2.8 million during FY2021.
  • Over the past 1 years, Cytokinetics' median Asset Writedowns and Impairment value was $2.8 million (recorded in 2021), while the average stood at $2.8 million.